Between 2015 and 2021, IO agents approved by the United States (US) Food and Drug Administration (FDA) as first- or second-line therapy for NSCLC without driver mutations included: the anti–PD-1 antibodies nivolumab, pembrolizumab, and cemiplimab; the anti–PD-L1 antibodies durvalumab and atezolizumab; and the anti–CTLA-4 antibody ipilimumab [17]. Here, PDCD1 is linked to non-small cell lung carcinoma.